Nektar Therapeutics (NKTR) Free Cash Flow (2010 - 2026)

Nektar Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$44.3 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 9.66% year-over-year to -$44.3 million in Q1 2026; TTM through Mar 2026 was -$203.9 million, a 14.45% decrease from a year earlier, with the FY2025 full-year figure at -$208.7 million, down 17.78% from the prior year.
• Free Cash Flow improved to -$44.3 million in Q1 2026 per NKTR's latest filing, from -$65.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$37.9 million in Q2 2024 and bottomed at -$92.6 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$48.9 million (2025), against an average of -$54.9 million.
• Across the five-year window, Free Cash Flow surged 63.02% in 2022 and plunged 39.3% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$58.2 million in 2022, then grew by 18.78% to -$47.3 million in 2023, then increased by 1.35% to -$46.6 million in 2024, then plunged by 39.3% to -$65.0 million in 2025, then surged by 31.8% to -$44.3 million in 2026.
• Per Business Quant, the three latest NKTR Free Cash Flow figures stand at -$44.3 million (Q1 2026), -$65.0 million (Q4 2025), and -$48.9 million (Q3 2025).